Previously presented in part at the American Academy of Dermatology (AAD) Annual Meeting, San Francisco, California, United States, 20–24 March 2015. Editorial assistance in the preparation of this manuscript was provided by Oxford PharmaGenesis Inc. Support for this assistance was funded by Novartis Pharmaceuticals Corporation. Sponsorship and article processing charges were funded by Novartis Pharmaceuticals Corporation. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. The authors received no financial support or other form of compensation related to the development of this manuscript.
Disclosures
Leon Kircik has served as a consultant and/or speaker and received honoraria from Abbott, Aclaris, Allergan, Amgen, Anacor Pharmaceuticals, Assos, Astellas, Biogen-Idec, Colbar, Celgene, Colla Genex, Connetics Corporation, Dermik Laboratories, Embil Pharmaceuticals, EOS, Ferndale Laboratories, Galderma, Genentech, Intendis, Innocutis, Innovail, Johnson & Johnson, Laboratory Skin Care, Leo, L’Oreal, 3 M, Medical International Technologies, Merck, Merz, Nano Bio, Novartis, Onset, OrthoNeutrogena, Promius, PediaPharma, PharmaDerm, PuraCap, Quinnova, Serono, SkinMedica, Stiefel Laboratories, Taro, Triax, UCB, Valeant Pharmaceuticals, Warner-Chilcott, and ZAGE. Dr. Kircik has also served as an investigator and received research grants from Acambis, Allergan, Amgen, Anacor Pharmaceuticals, Astellas, Asubio, Berlex Laboratories, Biolife, Biopelle, Boehringer-Ingelheim, Breckinridge Pharma, Celgene, Centocor, CollaGenex, Combinatrix, Connetics Corporation, Coria, Dermira, Dow Pharmaceutical Sciences, Dusa, Eli Lilly, Ferndale Laboratories, Galderma, Genentech, GlaxoSmithKline, Health Point, Idera, Intendis, Johnson & Johnson, Leo, L’Oreal, 3 M, Maruho, Medicis Pharmaceuticas Corp, Nano Bio, Novartis, Noven Pharmaceuticals, Nucryst Pharmaceuticals Corp, Obagi, Onset, OrthoNeutrogena, Promius, QLT, PharmaDerm, Pfizer, Quinnova, Quatrix, SkinMedica, Stiefel Laboratories, Toler Rx, UCB, Valeant Pharmaceuticals, Warner-Chilcott, and XenoPort. Dr. Kircik holds stock in Johnson & Johnson. Joseph Fowler has served as a consultant and/or speaker and received honoraria from Bayer, Galderma, GSK, Innocutis, Johnson & Johnson, Quinnova, Ranbaxy, and SmartPractice. Dr. Fowler has also served as an investigator and received research grants from 3 M, Abbot, Allergan, Amgen, Anacor, Astelles, Celgene, Centocor-Janssen, Chugai, Dermik, Galderma, Johnson & Johnson, Lilly, Medicis-Valeant, Merck, Novartis, OnSet, Pfizer, Quinnova, SmartPractice, Taisho, Taro, and Valeant. Jonathan Weiss has served as a consultant and received honoraria from Celgene, Galderma, Leo, Promius and Valeant. Dr. Weiss has also served as an investigator and received research grants from Allergan, Amgen, Celgene, Galderma, Leo, Novartis, Promius, Valeant and, Xenoport. Xiangyi Meng is an employee of Novartis. Adriana Guana is an employee of Novartis. Judit Nyirady is an employee of Novartis.
Compliance with Ethics Guidelines
This article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.
Open Access
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.